

H g K g E cha ge, a d C ea g L ed a d The S c E cha ge f H g K g L ed a e e, b f he c e, f h, a ce e, a e e e e a a, acc ac c e e e, a d e e, d, c a a ab ha, e f a, h, e a, g f e a ce he h e a a f he c e, f h, a ce e.

FOSUN PHARMA 复星医药

上海復星醫藥(集團)股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a c ed c a c a ed he Pe e, Re b c f Ch a h ed ab)

(Stock Code: 02196)

2019 THIRD QUARTERLY REPORT

T 13.09(2) R 13.10B R G L S T S E H K L I I P P I A S R O (C . 571 L H K).

T 2019 S F P (G) C . L * ("Company", "Group") ("2019 Third Quarterly Report"). T PRC A S B E .

B B

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chen Qiyu

Cha a

S P R C 29 O 2019

A a he da e f h, a ce e, he e ec d ec, f he C a a e M . Che Q , M . Ya Fa g a d M . W Yfa g; he e ec d ec, f he C a a e M . X Xa a g, M . Wa g Ca , M . M Ha g a d M . La g Ja fe g; a d he de e de e ec d ec, f he C a a e M . Ja g Xa , D . W g T Ya Ke -, M . L L g a d M . Ta g G a g.

* f de fca e,

| | | | | | | |
|--|--|--|--|--|--|--|
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| The shareholding status of the Top 10 unrestricted shareholders | | | |
|---|---|---------------------------|---------------|
| Name of the shareholders | Number of unrestricted tradable shares held | Type and number of shares | |
| | | Type | Number |
| SHANGHAI FOSUN HIGH TECHNOLOGY (GROUP) COMPANY LIMITED* | 938,095,290 | RMB ordinary shares | 938,095,290 |
| HKSCC NOMINEES LIMITED (Note 1) | 551,255,448 | Ordinary shares | 551,255,448 |
| CHINA SECURITIES FINANCE CORPORATION LIMITED* | 38,736,157 | RMB ordinary shares | 38,736,157 |
| HONG KONG SECURITIES CLEARING COMPANY LIMITED (Note 2) | 36,199,707 | RMB ordinary shares | 36,199,707 |
| NATIONAL SOCIAL SECURITY FUND 113 PORTFOLIO* | 28,066,210 | RMB ordinary shares | 28,066,210 |
| BASIC PENSION INSURANCE FUND 802 PORTFOLIO* | 25,824,892 | RMB ordinary shares | 25,824,892 |
| CENTRAL HONGKONG ASSET MANAGEMENT LTD.* | 24,067,700 | RMB ordinary shares | 24,067,700 |
| NATIONAL SOCIAL SECURITY FUND 110 PORTFOLIO* | 15,358,518 | RMB ordinary shares | 15,358,518 |
| ABU DHABI INVESTMENT AUTHORITY | 13,790,532 | RMB ordinary shares | 13,790,532 |
| CHINA CONSTRUCTION BANK CORPORATION – CHINA-EUROPEAL ENERGY SECURITIES INVESTMENT FUND* | 10,198,273 | RMB ordinary shares | 10,198,273 |
| Details of the shareholdings of the Top 10 unrestricted shareholders | Total | Ordinary shares | 3,493,500,000 |
| Details of the shareholdings of the Top 10 unrestricted shareholders | Number | | |

Note 1: HKSCC NOMINEES LIMITED, a wholly-owned subsidiary of HSBC, is the registered holder of 551,255,448 ordinary shares of the Company, representing 1.37% of the total number of shares of the Company. The shares are held in the name of the Company's registered office, HSBC NOMINEES (HONG KONG) LIMITED, ("Fosun High Tech") in Hong Kong.

Note 2: HONG KONG SECURITIES CLEARING COMPANY LIMITED is a wholly-owned subsidiary of HSBC.

2.3 The shareholdings of the Top 10 unrestricted shareholders of the Company as at the end of the reporting period are as follows:

Number

(3) Statement of Cash Flow

Unit: RMB

| Statement of Cash Flow | | | | |
|---|-------------------|-------------------|-----------------|--|
| Items | Jan – Sept 2019 | Jan – Sept 2018 | Ratio of change | Reasons of changes |
| Net change in cash and cash equivalents | -2,560,243,375.55 | -4,338,289,449.60 | 40.98% | Mainly due to the increase in cash and cash equivalents from the disposal of subsidiaries and the decrease in cash and cash equivalents from the disposal of subsidiaries and the decrease in cash and cash equivalents from the disposal of subsidiaries. |
| Exchange rate changes | 47,762,255.60 | -31,014,791.25 | 254.00% | Mainly due to the increase in cash and cash equivalents from the disposal of subsidiaries and the decrease in cash and cash equivalents from the disposal of subsidiaries. |

- 3.2 Analysis of the change in cash and cash equivalents
- The 2016 net change in cash and cash equivalents is RMB10,208 million, which is mainly due to the net change in cash and cash equivalents from the disposal of subsidiaries (RMB10,208 million) and the net change in cash and cash equivalents from the disposal of subsidiaries (RMB10,208 million).

The 2017 net change in cash and cash equivalents is RMB5 million, which is mainly due to the net change in cash and cash equivalents from the disposal of subsidiaries (RMB5 million) and the net change in cash and cash equivalents from the disposal of subsidiaries (RMB5 million).

The 2018 net change in cash and cash equivalents is RMB300 million, which is mainly due to the net change in cash and cash equivalents from the disposal of subsidiaries (RMB300 million) and the net change in cash and cash equivalents from the disposal of subsidiaries (RMB300 million).
 - The 2019 net change in cash and cash equivalents is RMB100 million, which is mainly due to the net change in cash and cash equivalents from the disposal of subsidiaries (RMB100 million) and the net change in cash and cash equivalents from the disposal of subsidiaries (RMB100 million).

The 2019 net change in cash and cash equivalents is RMB100 million, which is mainly due to the net change in cash and cash equivalents from the disposal of subsidiaries (RMB100 million) and the net change in cash and cash equivalents from the disposal of subsidiaries (RMB100 million).

At the end of the reporting period, the Company had 2,560,000 H Shares outstanding, which were valued at RMB53.54 per share. The Company's share price on the Shanghai Stock Exchange at the end of the reporting period was 0.10% higher than the closing price of the Company's shares on the Shanghai Stock Exchange on 31 December 2019.

3. On 27 November 2018, the Company issued 10,000,000 H Shares to Shanghai Henlius Biotech, Inc. ("Shanghai Henlius"), a company listed on the Hong Kong Stock Exchange (HKSE) ("Hong Kong Stock Exchange").

On 25 September 2019, the Company issued 1,000,000 H Shares to Shanghai Henlius Biotech, Inc. ("Shanghai Henlius"), a company listed on the HKSE. The Company's share price on the HKSE at the end of the reporting period was HK\$49.60 per share, which was 53.76% higher than the closing price of the Company's shares on the HKSE on 30 September 2019, which was HK\$3,208.89 per share.

On 17 October 2019, the Company issued 4,366,400 H Shares to Shanghai Henlius Biotech, Inc. ("Shanghai Henlius"), a company listed on the HKSE. The Company's share price on the HKSE at the end of the reporting period was HK\$210.49 per share, which was 53.33% higher than the closing price of the Company's shares on the HKSE on 30 September 2019, which was HK\$137.31 per share.

3.3 Financial Results

Net Income

3.4 Financial Results

Net Income

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
 Listed on the Shanghai Stock Exchange: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
 Listed on the Hong Kong Stock Exchange: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
 29 October 2019

4. APPENDICES

4.1 Financial statements

Consolidated balance sheet

30 September 2019

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: RMB Tenthousand Yuan

| Items | 30 September 2019 | 31 December 2018 |
|---|-------------------|-------------------|
| Current assets: | | |
| Cash and cash equivalents | 10,307,237,302.85 | 8,546,521,777.04 |
| Financial assets measured at fair value | 1,344,673,568.10 | 616,123,764.39 |
| Accounts receivable | 258,620,513.78 | 712,510,581.95 |
| Other receivables | 4,463,034,533.86 | 3,623,640,740.82 |
| Prepaid expenses | 471,597,865.70 | — |
| Other current assets | 596,927,301.93 | 472,144,580.30 |
| Other financial assets | 577,591,869.92 | 447,434,579.55 |
| Investments in subsidiaries | 9,995,755.01 | 11,660,016.68 |
| Investments in associates | 36,917,475.21 | 19,731,451.25 |
| Investments in structured entities | 3,858,842,830.18 | 3,287,392,199.46 |
| Non-current financial assets | — | — |
| Other non-current assets | 1,162,820,637.56 | — |
| Other non-current financial assets | 368,970,686.90 | 295,958,970.62 |
| Other non-current assets | 23,410,317,110.78 | 18,001,727,194.13 |
| Non-current assets: | | |
| Property, plant and equipment | 117,956,750.00 | 67,562,000.00 |
| Intangible assets | 21,198,447,942.66 | 21,427,527,810.80 |
| Other non-current assets | 100,986,503.54 | 126,313,106.69 |
| Other non-current financial assets | 2,100,733,208.89 | 2,505,806,955.75 |
| Financial assets measured at fair value | 7,291,387,236.53 | 7,083,251,505.14 |
| Other non-current assets | 2,942,095,697.03 | 2,039,800,319.91 |
| Right-of-use assets | 433,996,758.51 | — |
| Investments in subsidiaries | 7,873,710,459.21 | 7,151,343,109.87 |
| Investments in associates | 2,676,735,574.42 | 2,040,773,501.88 |
| Investments in structured entities | 9,187,137,617.57 | 8,853,913,413.52 |
| Other non-current assets | 114,180,385.70 | 95,198,631.30 |
| Other non-current financial assets | 242,021,035.79 | 173,134,814.17 |
| Other non-current assets | 879,591,445.02 | 985,009,024.32 |
| Other non-current financial assets | 55,158,980,614.87 | 52,549,634,193.35 |
| Other non-current assets | 78,569,297,725.65 | 70,551,361,387.48 |

Consolidated balance sheet (Continued)

30 September 2019

| Items | 30 September 2019 | 31 December 2018 |
|---|-------------------|-------------------|
| Current liabilities: | | |
| Short-term borrowings | 7,440,018,220.78 | 5,607,192,955.63 |
| Bank deposits | 266,942,486.20 | 149,003,072.96 |
| Trade payables | 2,233,670,981.77 | 2,184,280,272.14 |
| Other payables | 562,709,265.76 | 578,701,499.77 |
| Trade receivables | 451,969,450.66 | 478,905,270.26 |
| Other receivables | 4,178,903,272.34 | 3,237,217,890.12 |
| Interest receivable | 220,768,148.00 | 187,344,429.18 |
| Dividends receivable | 139,956,011.68 | 125,420,505.60 |
| Contract liabilities | 388,047,456.85 | 530,896,724.79 |
| Non-current liabilities | 2,206,056,772.37 | 4,929,603,365.34 |
| Other non-current liabilities | 1,599,149,293.47 | 227,445,337.32 |
| Total current liabilities | 19,327,467,200.20 | 17,923,246,388.33 |
| Non-current liabilities: | | |
| Long-term borrowings | 8,816,140,333.28 | 8,630,661,547.43 |
| Bank deposits | 5,781,204,728.90 | 4,039,456,986.21 |
| Long-term payables | 307,212,833.42 | — |
| Long-term receivables | 252,679,111.96 | 416,889,805.19 |
| Dividends payable | 358,341,043.66 | 363,489,177.57 |
| Dividends receivable | 2,895,818,060.31 | 2,908,359,008.27 |
| Other non-current liabilities | 2,878,227,018.69 | 2,676,545,098.82 |
| Total non-current liabilities | 21,289,623,130.22 | 19,035,401,623.49 |
| Total non-current liabilities | 40,617,090,330.42 | 36,958,648,011.82 |
| Equity: | | |
| Parent's equity (attributable to parent) | 2,562,898,545.00 | 2,563,060,895.00 |
| Contract liabilities | 11,918,086,638.94 | 10,544,648,359.54 |
| Minority interest | — | 1,711,169.00 |
| Other equity | -238,833,703.62 | -274,779,732.99 |
| Shareholders' equity | 2,373,685,050.45 | 2,374,999,312.51 |
| Reserves | 14,017,910,346.50 | 12,771,518,762.43 |
| Total equity (attributable to parent and minority interest) | 30,633,746,877.27 | 27,977,736,427.49 |
| Non-current liabilities | 7,318,460,517.96 | 5,614,976,948.17 |
| Total equity (attributable to parent) | 37,952,207,395.23 | 33,592,713,375.66 |
| Total equity (attributable to parent and minority interest) | 78,569,297,725.65 | 70,551,361,387.48 |

Legal Representative
Chen Qiyu

Chief Financial Officer:
Guan Xiaohui

Director of the Accounting Department:
Chen Zhanyu

Balance Sheet of the Parent Company

30 September 2019

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: RMB Ten Thousand Yuan

| Items | 30 September 2019 | 31 December 2018 |
|---|-------------------|-------------------|
| Current assets: | | |
| Cash and cash equivalents | 1,106,498,344.52 | 850,102,168.54 |
| Financial assets at fair value through profit or loss | | |
| Prepaid expenses | | |
| Other receivables | 6,407,634,690.21 | 6,914,735,852.92 |
| Inventory | 299,410,098.84 | 230,691,574.83 |
| Due from related parties | 354,609,680.05 | 307,409,680.05 |
| Intangible assets | — | — |
| Non-current financial assets | 2,536,000,000.00 | 1,625,000,000.00 |
| Other non-current assets | 239,000,000.00 | 158,570,000.00 |
| Total current assets | 10,289,133,034.73 | 9,548,408,021.46 |
| Non-current assets: | | |
| Due to related parties | 6,011,804,080.60 | 5,465,151,645.71 |
| Long-term equity investments | 23,961,991,164.92 | 22,999,277,541.00 |
| Other non-current financial assets | 37,689,534.30 | 37,626,487.24 |
| Other non-current assets | 147,179,403.98 | 184,188,803.45 |
| Fixed assets | 6,217,807.54 | 7,158,298.77 |
| Construction in progress | 2,305,418.41 | 2,305,418.41 |
| Intangible assets | 1,398,139.68 | 1,840,272.04 |
| Deferred tax assets | | |
| Goodwill | | |
| Long-term prepayments | | |
| Deferred tax liabilities | | |
| Total non-current assets | 30,168,585,549.43 | 28,697,548,466.62 |
| Total assets | 40,457,718,584.16 | 38,245,956,488.08 |

Balance Sheet of the Parent Company (Continued)

30 September 2019

| Items | 30 September 2019 | 31 December 2018 |
|---------------------------------|-------------------|-------------------|
| Current liabilities: | | |
| Short-term borrowings | 3,825,000,000.00 | 2,959,000,000.00 |
| Trade payables | | |
| Accounts receivable | | |
| Contract liabilities | | |
| Prepaid expenses | 94,480,035.63 | 124,637,901.93 |
| Other payables | 25,239,506.72 | 43,694,651.68 |
| Contract liabilities | 1,715,449,403.09 | 1,357,247,173.94 |
| Income tax payable | 213,542,735.45 | 172,658,261.16 |
| Deferred income tax | 229,468.00 | 229,468.00 |
| Other non-current liabilities | 1,267,088,795.71 | 3,769,010,861.94 |
| Other non-current liabilities | 1,304,675,980.01 | 5,313,103.87 |
| Total current liabilities | 8,231,933,721.16 | 8,258,903,693.36 |
| Non-current liabilities: | | |
| Long-term borrowings | 346,740,000.00 | 66,740,000.00 |
| Long-term payables | 5,781,204,728.90 | 4,039,456,986.21 |
| Long-term payables | | |
| Deferred income tax | 325,000.00 | 550,000.00 |
| Deferred income tax | 1,151,018,873.79 | 1,151,018,873.79 |
| Other non-current liabilities | | |
| Total non-current liabilities | 7,279,288,602.69 | 5,257,765,860.00 |
| Total non-current liabilities | 15,511,222,323.85 | 13,516,669,553.36 |
| Equity: | | |
| Parent's equity | 2,562,898,545.00 | 2,563,060,895.00 |
| Capital | 14,247,927,508.28 | 14,231,054,756.04 |
| Reserves | — | 1,711,169.00 |
| Other equity | -327,370,661.53 | -279,100,142.24 |
| Shareholders' equity | 1,247,565,522.50 | 1,247,565,522.50 |
| Other equity | 7,215,475,346.06 | 6,968,417,072.42 |
| Total equity | 24,946,496,260.31 | 24,729,286,934.72 |
| Total equity | 40,457,718,584.16 | 38,245,956,488.08 |

Legal Representative:
Chen Qiyu

Chief Financial Officer:
Guan Xiaohui

Director of Accounting Department:
Chen Zhanyu

Consolidated Income Statement (Continued)

January – September 2019

| Items | July – Sept 2019 | July – Sept 2018 | Jan – Sept 2019 | Jan – Sept 2018 |
|---|------------------|------------------|------------------|------------------|
| I. Operating Profit | -9,016,755.16 | -122,010,941.32 | 34,958,479.93 | -532,197,468.31 |
| Operating Profit from Continuing Operations | 7,142,372.12 | -173,180,224.69 | 35,946,029.37 | -571,964,925.72 |
| () Operating Profit from Discontinued Operations | 144,152.81 | 3,756,815.51 | -26,694,169.11 | -101,521,914.06 |
| 1. Continuing Operations | — | — | — | — |
| 2. Discontinued Operations | — | — | — | — |
| 3. Continuing Operations | 144,152.81 | 3,756,815.51 | -26,694,169.11 | -101,521,914.06 |
| 4. Discontinued Operations | — | — | — | — |
| () Operating Profit from Discontinued Operations | 6,998,219.31 | -176,937,040.20 | 62,640,198.48 | -470,443,011.66 |
| 1. Continuing Operations | -27,514,726.87 | 22,492,035.64 | -57,540,529.80 | 29,149,580.97 |
| 2. Discontinued Operations | 34,512,946.18 | -199,429,075.84 | 120,180,728.28 | -499,592,592.63 |
| Operating Profit from Discontinued Operations | -16,159,127.28 | 51,169,283.37 | -987,549.44 | 39,767,457.41 |
| II. Total Operating Profit | 626,951,292.40 | 479,073,767.81 | 2,490,555,469.23 | 1,806,839,053.77 |
| Total Operating Profit from Continuing Operations | 554,726,673.16 | 360,501,362.79 | 2,099,650,177.36 | 1,522,187,428.09 |
| Total Operating Profit from Discontinued Operations | 72,224,619.24 | 118,572,405.02 | 390,905,291.87 | 284,651,625.68 |
| III. Earnings | | | | |
| () Basic Earnings | 0.22 | 0.20 | 0.81 | 0.83 |
| () Diluted Earnings | 0.22 | 0.20 | 0.81 | 0.83 |

Legal Representative:
Chen Qiyu

Chief Financial Officer:
Guan Xiaohui

Director of Accounting Department:
Chen Zhanyu

Income Statement of the Parent Company

January – September 2019

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: RMB Ten Thousand Yuan

| Items | July – Sept 2019 | July – Sept 2018 | Jan – Sept 2019 | Jan – Sept 2018 |
|-------------------------------|------------------|------------------|------------------|------------------|
| I. Operating Profit | 3,815,974.06 | — | 5,685,313.69 | 9,433.96 |
| Loss | — | — | — | — |
| Trade Receivables | 1,138,885.77 | — | 2,411,699.94 | 43,754.06 |
| Share of Profit of Associates | — | — | — | — |
| Government Grants | 65,458,328.69 | 72,278,881.00 | 136,505,943.90 | 151,588,516.01 |
| Research Expenses | 1,400,270.20 | — | 2,952,245.60 | — |
| Finance Expenses | 24,847,472.18 | 29,794,031.27 | 105,319,187.87 | 78,043,266.55 |
| Income Tax | 143,806,935.92 | 120,916,769.27 | 411,681,720.73 | 331,017,960.01 |
| Interest Income | 110,395,009.96 | 101,566,901.47 | 300,636,180.35 | 266,631,390.40 |
| Assets Impairment | — | — | — | — |
| Cost of Disposal | — | — | — | — |
| Profit on Disposal | 110,486.49 | 75,000.00 | 300,849.09 | 225,000.00 |
| Income Tax (“-”) | 438,727,482.59 | 409,853,353.52 | 1,342,948,533.13 | 1,328,284,941.99 |
| Income Tax (“-”) | 430,736,612.25 | 389,199,792.25 | 1,250,403,969.29 | 1,156,577,651.49 |
| Government Grants (“-”) | — | — | — | — |
| Government Grants (“-”) | -14,794,694.59 | 66,221,631.43 | -36,067,868.78 | 90,531,856.25 |
| Government Grants (“-”) | 7,349.80 | -886.58 | 7,349.80 | -886.58 |
| II. Operating Profit (“-”) | 335,021,641.51 | 374,076,186.10 | 1,065,685,099.62 | 1,189,374,809.00 |
| Profit on Disposal | — | — | — | — |
| Loss on Disposal | — | — | — | — |
| III. Total Profit (“-”) | 335,021,641.51 | 374,076,186.10 | 1,065,685,099.62 | 1,189,374,809.00 |
| Loss on Disposal | — | — | — | — |
| IV. Net Profit (“-”) | 335,021,641.51 | 374,076,186.10 | 1,065,685,099.62 | 1,189,374,809.00 |
| () Net Profit (“-”) | 335,021,641.51 | 374,076,186.10 | 1,065,685,099.62 | 1,189,374,809.00 |
| () Net Profit (“-”) | — | — | — | — |



| Items | 31 December 2018 | 1 January 2019 | Adjustment |
|---|-------------------|-------------------|-----------------|
| Non-current liabilities: | | | |
| Long-term debt | 8,630,661,547.43 | 8,630,661,547.43 | |
| Bank deposits | 4,039,456,986.21 | 4,039,456,986.21 | |
| Interest payable | — | — | |
| Provision for doubtful accounts | — | — | |
| Long-term debt | — | 325,992,167.00 | -325,992,167.00 |
| Long-term debt | 416,889,805.19 | 398,095,841.52 | 18,793,963.67 |
| Dividends payable | 363,489,177.57 | 363,489,177.57 | |
| Dividends payable | 2,908,359,008.27 | 2,908,359,008.27 | |
| Other | 2,676,545,098.82 | 2,676,545,098.82 | |
| Total | 19,035,401,623.49 | 19,342,599,826.82 | -307,198,203.33 |
| Total | 36,958,648,011.82 | 37,348,299,890.45 | -389,651,878.63 |
| Equity (or shareholders' interests): | | | |
| Preferred stock | 2,563,060,895.00 | 2,563,060,895.00 | |
| Common stock | 10,544,648,359.54 | 10,544,648,359.54 | |
| Long-term debt | 1,711,169.00 | 1,711,169.00 | |
| Other | -274,779,732.99 | -274,779,732.99 | |
| Shareholders' equity | 2,374,999,312.51 | 2,374,999,312.51 | |
| Shareholders' equity | 12,771,518,762.43 | 12,771,518,762.43 | |
| Total | 27,977,736,427.49 | 27,977,736,427.49 | |
| Non-current liabilities | 5,614,976,948.17 | 5,614,976,948.17 | |
| Total Equity (or shareholders' interests) | 33,592,713,375.66 | 33,592,713,375.66 | |
| Total | 70,551,361,387.48 | 70,941,013,266.11 | -389,651,878.63 |

Equity (or shareholders' interests):

For 1 January 2019, the Group's net assets were 70,941,013,266.11 yuan, of which 33,592,713,375.66 yuan was contributed by shareholders. The Group's net assets were 70,551,361,387.48 yuan as at 31 December 2018.

The Group's net assets were 70,551,361,387.48 yuan as at 31 December 2018, of which 33,592,713,375.66 yuan was contributed by shareholders. The Group's net assets were 70,941,013,266.11 yuan as at 1 January 2019, of which 33,592,713,375.66 yuan was contributed by shareholders.

Balance Sheet of the Parent Company

Unit: RMB

| Items | 31 December 2018 | 1 January 2019 | Adjustment |
|---|-------------------|-------------------|------------|
| Current assets: | | | |
| Cash | 850,102,168.54 | 850,102,168.54 | |
| Accounts receivable | 6,914,735,852.92 | 6,914,735,852.92 | |
| Inventory | 230,691,574.83 | 230,691,574.83 | |
| Due to related parties | 307,409,680.05 | 307,409,680.05 | |
| Non-current receivables | 1,625,000,000.00 | 1,625,000,000.00 | |
| Other receivables | 158,570,000.00 | 158,570,000.00 | |
| Total | 9,548,408,021.46 | 9,548,408,021.46 | |
| Non-current assets: | | | |
| Derivative financial assets | 5,465,151,645.71 | 5,465,151,645.71 | |
| Long-term equity investments | 22,999,277,541.00 | 22,999,277,541.00 | |
| Other non-current assets | 37,626,487.24 | 37,626,487.24 | |
| Other non-current receivables | 184,188,803.45 | 184,188,803.45 | |
| Financial assets at fair value through profit or loss | 7,158,298.77 | 7,158,298.77 | |
| Contract assets | 2,305,418.41 | 2,305,418.41 | |
| Intangible assets | 1,840,272.04 | 1,840,272.04 | |
| Total | 28,697,548,466.62 | 28,697,548,466.62 | |
| Total | 38,245,956,488.08 | 38,245,956,488.08 | |
| Current liabilities: | | | |
| Short-term debt | 2,959,000,000.00 | 2,959,000,000.00 | |
| Accounts payable | 124,637,901.93 | 124,637,901.93 | |
| Trade payables | 43,694,651.68 | 43,694,651.68 | |
| Other payables | 1,357,247,173.94 | 1,357,247,173.94 | |
| Inventory | 172,658,261.16 | 172,658,261.16 | |
| Due to related parties | 229,468.00 | 229,468.00 | |
| Non-current payables | 3,769,010,861.94 | 3,769,010,861.94 | |
| Other payables | 5,313,103.87 | 5,313,103.87 | |
| Total | 8,258,903,693.36 | 8,258,903,693.36 | |

| Items | 31 December 2018 | 1 January 2019 | Adjustment |
|---|-------------------|-------------------|------------|
| Non-current liabilities: | | | |
| Long-term debt | 66,740,000.00 | 66,740,000.00 | |
| Bank deposits | 4,039,456,986.21 | 4,039,456,986.21 | |
| Interest payable | — | — | |
| Provision for doubtful accounts | — | — | |
| Deferred income taxes | 550,000.00 | 550,000.00 | |
| Deferred tax assets | 1,151,018,873.79 | 1,151,018,873.79 | |
| Trade payables | 5,257,765,860.00 | 5,257,765,860.00 | |
| Trade receivables | 13,516,669,553.36 | 13,516,669,553.36 | |
| Equity (including minority interest): | | | |
| Preferred shares | 2,563,060,895.00 | 2,563,060,895.00 | |
| Common shares | 14,231,054,756.04 | 14,231,054,756.04 | |
| Reserves | 1,711,169.00 | 1,711,169.00 | |
| Other | -279,100,142.24 | -279,100,142.24 | |
| Share-based payments | 1,247,565,522.50 | 1,247,565,522.50 | |
| Share-based payments reserve | 6,968,417,072.42 | 6,968,417,072.42 | |
| Trade payables (including minority interest) | 24,729,286,934.72 | 24,729,286,934.72 | |
| Trade receivables (including minority interest) | 38,245,956,488.08 | 38,245,956,488.08 | |

4.3 Explanation on retrospective adjustments to previous comparative data for the initial implementation of New Financial Instruments Standards and New Lease Standards

For 1 January 2019, the Group applied the New Lease Standards and New Financial Instruments Standards retrospectively to the beginning of the reporting period (MOF).

The Group's financial statements for 2019 are presented in accordance with the New Lease Standards and New Financial Instruments Standards. The Group's financial statements for 2018 are presented in accordance with the previous standards. The Group's financial statements for 2019 are presented in accordance with the New Lease Standards and New Financial Instruments Standards. The Group's financial statements for 2018 are presented in accordance with the previous standards.

4.4 Audited report

Not applicable